To hear about similar clinical trials, please enter your email below
Trial Title:
Evaluation of the Prognostic Impact of Decreased Serum beta2 Microglobulin in the First Year of Follow-up of Myeloproliferative Neoplasia (PRODIGE)
NCT ID:
NCT06553638
Condition:
Myeloproliferative Neoplasm
Conditions: Official terms:
Myeloproliferative Disorders
Study type:
Observational
Overall status:
Active, not recruiting
Study design:
Time perspective:
Prospective
Summary:
50 patients with a diagnosis of MPN will have an assessment of b2microglobuline at
diagnosis and after 1 year. b2mic value decrease will be compared to treatment response.
Criteria for eligibility:
Study pop:
Patients with a new diagnosis of MPN
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:
- MPN patient diagnosed at one of the participating centers
- over 18 yo
Exclusion Criteria:
- Not able to consent
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Locations:
Facility:
Name:
Chu Brest
Address:
City:
Brest
Zip:
29609
Country:
France
Start date:
August 12, 2024
Completion date:
May 31, 2026
Lead sponsor:
Agency:
University Hospital, Brest
Agency class:
Other
Source:
University Hospital, Brest
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT06553638
